PREDICT vs CTS5 vs Oncotype Breast Prognosis Tools

2. PREDICT vs CTS5 vs Oncotype DX vs BCI

3. Practical Workflow Across the Breast Cancer Timeline

1. At initial post-operative planning: generate and interpret the estimate at the official PREDICT Breast tool.
2. When chemotherapy benefit is uncertain in HR-positive/HER2-negative disease: consider genomic assays only if the patient matches the validated and guideline-supported population. Interpret the result with age, menopausal status, nodal status, and patient priorities.
3. During years 0-5 of endocrine therapy: focus on adherence, toxicity management, ovarian function suppression where indicated, bone health, and recurrence surveillance. Early prognostic tools should not be re-used as if they were dynamic recurrence monitors.
4. At the 5-year endocrine therapy decision point: use CTS5 to estimate residual late distant recurrence risk and consider BCI or other genomic information if available and appropriate.
5. Before changing treatment: document the exact clinical question, tool version, patient eligibility, and how the estimate influenced shared decision-making.

4. Tool-by-Tool Guidance

4.1 PREDICT Breast: official population-estimate result

PREDICT is an official online model that displays population estimates for women with early invasive breast cancer after surgery. OncoToolkit does not recreate that model: its route records a verified official v3.1 output and preserves the displayed treatment combination.

The recorder is limited to the exact supported v3.1 build. A post-neoadjuvant record requires the documented pretherapy size and carries a warning; metastatic disease, DCIS/LCIS alone, unsupported builds, and uncertain source reports are withheld.

Useful reference: PREDICT Breast official tool guide.

4.2 CTS5: residual late distant recurrence risk

CTS5 was developed as a simple clinicopathologic score for women with ER-positive primary breast cancer who completed 5 years of endocrine therapy and remained free of distant recurrence. It uses age, tumor size, grade, and nodal burden to categorize residual risk over years 5-10.

The key strength is practicality: the inputs are available from routine pathology and clinical records. The key limitation is equally important: CTS5 estimates risk, not endocrine therapy benefit. A high CTS5 score supports a more serious discussion about extended endocrine therapy, but the final decision should also consider prior toxicity, bone health, menopausal status, comorbidities, adherence, patient preference, and genomic information if available.

Useful internal links: CTS5 calculator and CTS5 guide.

4.3 Oncotype DX: source-specific external-report context

Oncotype DX reports a 21-gene Recurrence Score. The TAILORx trial clarified that many node-negative patients with intermediate scores do not benefit from chemotherapy, while younger patients at the higher end of the intermediate range may warrant more nuanced discussion. RxPONDER extended evidence to patients with 1-3 positive nodes and Recurrence Score 0-25, where menopausal status strongly affects interpretation.

Use Oncotype DX only in clinically eligible disease settings. It should not be used to de-escalate therapy in HER2-positive, triple-negative, inflammatory, metastatic, or high-nodal-burden scenarios outside its validated role.

Useful internal links: Oncotype DX report interpreter and Oncotype DX source guide.

4.4 Breast Cancer Index: extended endocrine therapy context

Breast Cancer Index is a genomic assay used in selected HR-positive early breast cancer scenarios. Interpret the final Biotheranostics/Hologic report using its current intended-use information and clinical guidance; OncoToolkit does not reproduce or reinterpret the proprietary assay.

Useful evidence overview: Breast Cancer Index and extended endocrine therapy.

5. Common Pitfalls

6. Frequently Asked Questions